 |
|
|
| |
Prevalence of Pretreatment NS5A and NS5B NI-Resistance Associated Substitutions in HCV-Infected Patients Enrolled in Clinical Trials in Asia
|
| |
| |
Reported by Jules Levin
APASL 2017 Feb 15-19 Shanghai, China
Lai Wei1, Masao Omata2, Young-Suk Lim3, Wan-Long Chuang4, Dao Long5, Xie Qing6, Jin Lin Hou 7, Jidong Jia8, Evguenia Svarovskaia9, Ross Martin9, Brian Doehle9, Jenny Yang9, Shampa De-Oertel9, Benedetta Massetto9, Kathryn Kersey9, Diana M. Brainard9, Hongmei Mo9, Nguyen Kinh10, Jia-Horng Kao11, Kwang-Hyub Han12, Masashi Mizokami13, Zhongping Duan14
1Peking University People's Hospital, Beijing, China; 2Yamanashi Prefectural Hospital Organization, Yamanashi, Japan
3Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; 4Kaohsiung Medical University Hospital, Kaohsiung Medical University, Taiwan; 5Bach Mai Hospital, Hanoi Medical University Hospital, Hanoi, Vietnam; 6Shanghai Jiaotonh University Ruijin Hospital, Shanghai, China; 7Nanfang Hospital of Southern Medical University, Guangzhou, China; 8Beijing Friendship Hospital Affiliated to Capital Medical University, Beijing, China; 9Gilead Sciences, Inc; Foster City, California, USA; 10National Hospital of Tropical Diseases, Hanoi, Vietnam; 11National Taiwan University College of Medicine and Hospital, Taipei, Taiwan; 12Yonsei University College of Medicine Seoul, South Korea; 13National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan; 14Beijing Youan Hospital Affiliated to Capital Medical University, Beijing, China
|
| |
|
|
|
|
|
